| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| Nangibotide | LR-12 | Phase 2 Clinical | Inotrem | Shock, Septic; Coronavirus Disease 2019 (COVID-19) | 상세 |
| CEL383 | CEL-383 | Phase 1 Clinical | Celsius Therapeutics Inc | Inflammatory Bowel Diseases | 상세 |
| ABBV-8736 | ABBV-8736 | Phase 1 Clinical | Abbvie Inc | Inflammatory Bowel Diseases | 상세 |
| TREM 1 antibody(Boehringer Ingelheim International Gmbh) | TREM 1 antibody(Boehringer Ingelheim International Gmbh) | Phase 1 Clinical | Boehringer Ingelheim International Gmbh | Immune System Diseases | 상세 |
| PY-159 | PY-159 | Phase 1 Clinical | Centre for the Commercialization of Antibodies and Biologics | Solid tumours; Neoplasms | 상세 |